Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LepVax (Advance Access & Delivery)
- Development stage
- Phase 1
- Lead developer
- Advanced Access & Delivery Institute
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
LepVax (LEP-F1 + GLA-SE) is a recombinant subunit vaccine developed for the prevention and treatment of leprosy, caused by *Mycobacterium leprae*. It consists of the LEP-F1 recombinant fusion protein, which combines three highly immunogenic *M. leprae* antigens (ML2531, ML2380, and ML2055), and the GLA-SE adjuvant (Glucopyranosyl Lipid Adjuvant in a Stable Emulsion). GLA-SE is a synthetic Toll-like receptor 4 (TLR4) agonist that enhances the Th1-type cellular immune response, which is essential for controlling intracellular mycobacterial infections. The vaccine is designed to provide long-term protection against infection and to potentially reduce the progression of the disease and associated nerve damage in paucibacillary and multibacillary leprosy patients. It was developed by the Infectious Disease Research Institute (IDRI), now the Advanced Access & Delivery Institute (AAHI), in collaboration with the Oswaldo Cruz Foundation (Fiocruz) and Bio-Manguinhos.
- Brand names
- LepVax
- Other names
- Leprosy Vaccine
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on LepVax (Advance Access & Delivery).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LepVax (Advance Access & Delivery).